Resmed (RSMDF) Revenue (2009 - 2026)

Resmed (RSMDF) has reported Revenue for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 8.58% year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2026 stood at $5.7 billion (up 9.85% YoY), and the FY2026 full-year result was $5.7 billion, up 9.85% from the prior year.
• Revenue improved to $1.5 billion in Q2 2026 per RSMDF's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Revenue topped out at $1.5 billion in Q2 2026 and bottomed at $864.5 million in Q1 2022.
• Historically, Revenue has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Revenue advanced 4.41% in 2022, then gained 29.2% in 2023.
• Over 5 years, Revenue stood at $1.0 billion in 2022, then increased by 12.48% to $1.2 billion in 2023, then rose by 10.26% to $1.3 billion in 2024, then rose by 10.98% to $1.4 billion in 2025, then climbed by 2.87% to $1.5 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $1.5 billion, $1.4 billion, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.